Carlson Capital Management lessened its position in shares of Solventum Co. (NYSE:SOLV – Free Report) by 30.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,927 shares of the company’s stock after selling 4,891 shares during the period. Carlson Capital Management’s holdings in Solventum were worth $762,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD acquired a new position in shares of Solventum during the first quarter worth $5,889,000. CWM LLC purchased a new stake in Solventum during the 2nd quarter worth about $473,000. Great Valley Advisor Group Inc. acquired a new position in Solventum in the second quarter valued at approximately $493,000. First Horizon Advisors Inc. purchased a new stake in shares of Solventum during the 2nd quarter worth approximately $58,000. Finally, Swedbank AB purchased a new position in shares of Solventum during the second quarter worth about $4,711,000.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on SOLV. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. Wells Fargo & Company cut their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. Wolfe Research began coverage on shares of Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. The Goldman Sachs Group lifted their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Finally, Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $68.00.
Solventum Stock Performance
NYSE:SOLV traded down $0.57 during midday trading on Tuesday, reaching $71.04. 83,404 shares of the company traded hands, compared to its average volume of 1,697,884. The company has a fifty day moving average price of $70.52 and a 200 day moving average price of $62.35. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
- Five stocks we like better than Solventum
- What is the Euro STOXX 50 Index?
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- What Are Dividends? Buy the Best Dividend Stocks
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- What Are the U.K. Market Holidays? How to Invest and Trade
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.